Novavax, Inc. (NasdaqGS:NVAX) Stock Price & Quote Analysis

NVAX Stock Overview

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs.

NVAX fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	0/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Rewards

Trading at 91.6% below our estimate of its fair value

Risk Analysis

Negative shareholders equity

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

Shareholders have been diluted in the past year

My Notes

New

Notes are coming soon

Novavax, Inc. Competitors

Lyell Immunopharma

NasdaqGS:LYEL

US$820.3m

Albireo Pharma

NasdaqCM:ALBO

US$930.3m

REGENXBIO

NasdaqGS:RGNX

US$1.0b

Alector

NasdaqGS:ALEC

US$793.9m

Price History & Performance

Summary of all time highs, changes and price drops for Novavax
Historical stock prices
Current Share Price	US$10.89
52 Week High	US$95.34
52 Week Low	US$8.75
Beta	1.72
1 Month Change	-11.17%
3 Month Change	-50.81%
1 Year Change	-88.14%
3 Year Change	48.97%
5 Year Change	-73.18%
Change since IPO	-86.39%

Recent updates

COVID-19 remains global health emergency - WHO

Oct 19

Novavax spikes ahead of presentations on COVID-19 vaccine portfolio

Oct 10

US Supreme Court declines to hear challenge of COVID vaccine mandate for health workers

Oct 03

Bearish: Analysts Just Cut Their Novavax, Inc. (NASDAQ:NVAX) Revenue and EPS estimates

Aug 11

Novavax COVID-19 shot is linked to rare cases of heart inflammation – EU agency

Aug 03

Novavax gets Japanese regulatory nod for use of its COVID vaccine in teens

Jul 26

Serum Institute of India supplies Novavax's COVID vaccine in US

Jul 18

Novavax to deliver 3.2M doses of COVID-19 vaccine to U.S.

Jul 11

Novavax wins EU nod to use COVID-19 vaccine in adolescents

Jul 05

Taiwan to get 504K doses of Novavax COVID vaccine in 1st lot this week

Jun 29

Novavax seeks label expansion for COVID-19 shot in Canada

Jun 23

The Novavax Vaccine, Finally

Jun 08

Is Novavax (NASDAQ:NVAX) Using Debt In A Risky Way?

May 24

Novavax: Buying Here Will Not End Well

May 18

Novavax: Don't Catch The Falling Knives

May 07

Novavax: Management's Revenue Guidance - If It Can Be Trusted - Makes The Bull Case

Apr 21

Novavax Stock Forecast: Where Is It Likely Heading By 2025?

Apr 05

Novavax: Disappointing Performance Despite Promises - Poor Outlook Ahead

Mar 30

Is Novavax Stock A Buy Or Sell As COVID-19 Shot Awaits FDA Approval?

Mar 04

Novavax Earnings Preview: Hold On Potential To Deliver Sizeable Vaccine Supply

Feb 24

Shareholder Returns

	NVAX	US Biotechs	US Market
7D	-3.0%	-0.8%	0.9%
1Y	-88.1%	3.9%	-10.9%

Return vs Industry: NVAX underperformed the US Biotechs industry which returned 3.9% over the past year.

Return vs Market: NVAX underperformed the US Market which returned -10.9% over the past year.

Price Volatility

Is NVAX's price volatile compared to industry and market?
NVAX volatility
NVAX Average Weekly Movement	16.1%
Biotechs Industry Average Movement	12.0%
Market Average Movement	6.7%
10% most volatile stocks in US Market	17.5%
10% least volatile stocks in US Market	2.8%

Stable Share Price: NVAX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: NVAX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
1987	1,541	John Jacobs	https://www.novavax.com

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics.

Novavax, Inc. Fundamentals Summary

How do Novavax's earnings and revenue compare to its market cap?
NVAX fundamental statistics
Market Cap	US$936.31m
Earnings (TTM)	-US$1.32b
Revenue (TTM)	US$1.85b

0.5x

P/S Ratio

-0.7x

P/E Ratio

Is NVAX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
NVAX income statement (TTM)
Revenue	US$1.85b
Cost of Revenue	US$2.66b
Gross Profit	-US$814.59m
Other Expenses	US$507.39m
Earnings	-US$1.32b

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-15.38
Gross Margin	-44.11%
Net Profit Margin	-71.59%
Debt/Equity Ratio	-57.3%

How did NVAX perform over the long term?

See historical performance and comparison

NVAX Stock Overview

Rewards

Risk Analysis

Novavax, Inc. Competitors

NasdaqGS:LYEL

US$820.3m

NasdaqCM:ALBO

US$930.3m

NasdaqGS:RGNX

US$1.0b

NasdaqGS:ALEC

US$793.9m

Price History & Performance

Recent News & Updates

High number of new directors

Novavax, Inc. announced that it has received $6.75 million in funding from River Private Wealth

Novavax, Inc. Announces Chief Executive Officer Changes

Novavax, Inc. Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates

Price target decreased to US$61.50

Novavax, Inc. has completed a Follow-on Equity Offering in the amount of $65 million.

Recent updates

High number of new directors

Novavax, Inc. announced that it has received $6.75 million in funding from River Private Wealth

Novavax, Inc. Announces Chief Executive Officer Changes

Novavax, Inc. Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates

Price target decreased to US$61.50

Novavax, Inc. has completed a Follow-on Equity Offering in the amount of $65 million.

Novavax, Inc. has completed a Follow-on Equity Offering in the amount of $65 million.

Novavax, Inc. Reaffirms Revenue Guidance for the Full Year 2022

Novavax, Inc. Appoints Richard J. Rodgers as Member of Its Audit Committee and as A Member of Its Compensation Committee

Novavax, Inc. Announces Nuvaxovid COVID-19 Vaccine Approval in Canada for Use as a Primary Series in Adolescents

No longer forecast to breakeven

Novavax, Inc. Announces the World Health Organization Issue an Updated Emergency Use Listing (EUL) for Nuvaxovid(TM) (NVX-CoV2373) COVID-19

Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults

Price target decreased to US$78.17

Consensus forecasts updated

Novavax, Inc. Announces Medicines and Healthcare Products Regulatory Agency Expands Conditional Marketing Authorization for Nuvaxovid™ COVID-19 Vaccine

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Novavax, Inc. Revises Revenue Guidance for the Year 2022

Novavax, Inc. to Report Q3, 2022 Results on Nov 08, 2022

U.S. FDA Grants Emergency Use Authorization for Novavax, Inc.'s COVID-19 Vaccine, Adjuvanted as a Booster for Adults

COVID-19 remains global health emergency - WHO

Novavax, Inc. Announces Positive Results from Phase 1/2 Clinical Trial of Its COVID-19-Influenza Combination (CIC) Vaccine Candidate

Novavax, Inc. Presents Data from the Phase 3 PREVENT-19 Trial and Study 307 (Lot Consistency) at the World Vaccine Congress Europe 2022

Forecast breakeven date pushed back to 2023

Novavax spikes ahead of presentations on COVID-19 vaccine portfolio

US Supreme Court declines to hear challenge of COVID vaccine mandate for health workers

Novavax makes 1M doses of its COVID-19 vaccine available for use in the UK

Forecast breakeven date pushed back to 2023

Price target decreased to US$106

Novavax Nuvaxovid™ COVID-19 Vaccine Receives Expanded Emergency Use Authorization in Taiwan for Use in Adolescents Aged 12 Through 17

Novavax and Serum Institute of India Announce Full Product Registration in South Africa of Novavax Covid-19 Vaccine as A Primary Series for Adults Aged 18 and Older

Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the European Union for Use as A Booster for Adults Aged 18 and Older

EU clears Novavax's COVID-19 shot for use as a booster dose in adults

Swissmedic Authorizes Novavax Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 and as a Booster in Adults Aged 18 and Older

Novavax Nuvaxovid COVID-19 Vaccine Recommended by CHMP for Expanded Conditional Marketing Authorization in the European Union as a Booster for Adults Aged 18 and Older

Novavax wins EU backing for COVID-19 booster shot

Novavax, Inc. Nuvaxovid™ Covid-19 Vaccine Granted Expanded Conditional Marketing Authorization in the United Kingdom for Use in Adolescents Aged 12 Through 17

Novavax: Finding Its Niche

Novavax, Inc. Announces Nuvaxovid COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand for Adolescents Aged 12 Through 17

Novavax, Inc. announces Nuvaxovid COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand as First and Second Booster for Adults

Novavax COVID vaccine gets provisional approval in New Zealand as booster shot

Novavax, Inc. Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older

Price target decreased to US$126

Novavax Q2: Time To Turn Bullish After The Massive Collapse

Bearish: Analysts Just Cut Their Novavax, Inc. (NASDAQ:NVAX) Revenue and EPS estimates

Forecast breakeven date pushed back to 2023

Novavax, Inc. Is Revises Revenue Guidance for Full Year 2022

Price target decreased to US$126

Novavax, Inc. Initiates Phase 2b/3 Hummingbird Global Clinical Trial for the Novavax Covid-19 Vaccine in Children Aged Six Months Through 11 Years

Novavax COVID-19 shot is linked to rare cases of heart inflammation – EU agency

Novavax, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Novavax Announces Expanded Approval of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 through 17 in Japan

Novavax gets Japanese regulatory nod for use of its COVID vaccine in teens

Serum Institute of India supplies Novavax's COVID vaccine in US

U.S. FDA Grants Emergency Use Authorization for Novavax, Inc. COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over

Novavax to deliver 3.2M doses of COVID-19 vaccine to U.S.

Novavax, Inc. Announces European Commission Approves Expanded Conditional Marketing Authorization of Nuvaxovid™ (NVX-CoV2373) COVID-19 Vaccine in European Union for Adolescents Aged 12 Through 17

Novavax wins EU nod to use COVID-19 vaccine in adolescents

Novavax, Inc. Presents Data At FDA VRBPAC Meeting Demonstrates Broad Antibody Responses to Both Prototype and Omicron-Specific Variants